• Johnson & Johnson announced Phase 3 FUZION results showing Tremfya sustained or improved fistula remission in adults with Crohn's disease through one year.
• Both maintenance regimens showed durable benefits in patients with perianal fistulas; safety findings remained consistent with Tremfya's established profile.
• The findings are being presented at the 2026 United European Gastroenterology Week.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610190800PR_NEWS_USPR_____NY73662) on October 19, 2026, and is solely responsible for the information contained therein.